

Literatura ACTA MEDICINAE 10/2017 Praktický lékař

- 2 **Kde kompetence praktického lékaře nestačí**
prof. MUDr. Milan Kvapil, CSc. Interní klinika FN Motol a 2. LF UK, Praha
- 2 **Průduškové astma a chronická obstrukční plicní nemoc**
prof. MUDr. Jiří Homolka, DrSc. I. klinika tuberkulózy a respiračních nemocí VFN a 1. LF UK, Praha
- 2 **Radioterapie v léčbě maligních nádorů kůže nemelanomového typu**
MUDr. Hana Doleželová Ph.D. | MUDr. Petra Hübnerová Klinika radiační onkologie, MOÚ, Brno
- 2 **Sekundární osteoporóza u zánětlivých revmatických onemocnění**
MUDr. David Suchý, Ph.D. Oddělení klinické farmakologie FN Plzeň, Ústav farmakologie 2. LF UK, Praha
MUDr. Radka Fuchsová Centrální radioizotopová laboratoř LF UK a FN Plzeň
- 3 **Moderní léčba kašle**
MUDr. Stanislav Kos, CSc., FCCP Český občanský spolek proti plicním nemocem, Praha
- 3 **Betablokátory a srdeční selhání**
prof. MUDr. Jindřich Špinar, CSc., FESC Interní kardiologická klinika, LF MU a FN Brno
prof. MUDr. Jiří Vítovec, CSc., FESC | prof. MUDr. Lenka Špinarová, Ph.D., FESC
Interní kardiologická klinika, LF MU a FNUSA, Brno
- 4 **Použití fixní trojkombinace atorvastatin, perindopril a amlodipin k terapii arteriální hypertenze a ke snížení rizika kardiovaskulárních příhod**
doc. MUDr. Filip Málek, Ph.D. Kardiovaskulární centrum Nemocnice na Homolce, Praha
- 4 **Arteriální hypertenze a antikoagulační léčba u starších a starých pacientů**
MUDr. Antonín Novák EUC Klinika, kardiologická ambulance, Ústí nad Labem
- 4 **Preskripce statinů v ordinaci praktického lékaře**
MUDr. Eva Tůmová, Ph.D. Centrum preventivní kardiologie, III. interní klinika 1. LF UK a VFN, Praha

Kde kompetence praktického lékaře nestačí

prof. MUDr. Milan Kvapil, CSc. Interní klinika FN Motol a 2. LF UK, Praha

- Inzucchi, S. E. – Bergenstal, R. M. – Buse, J. B., et al.: Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetologia*, 2015, 58, s. 429–442.
- Nathan, D. M. – Cleary, P. A. – Backlund, J. Y., et al.: Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med*, 2005, 353, s. 2643–2653.
- Stratton, I. M. – Adler, A. I. – Neil, H. A., et al.: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ*, 2000, 321, s. 405–412.
- Reaven, G. M.: Syndrome X. *Blood Press Suppl*, 1992, 4, s. 13–16.
- Reaven, G. M.: Role of insulin resistance in human disease (syndrome X): an expanded definition. *Annu Rev Med*, 1993, 44, s. 121–131.
- Reaven, G. M.: Syndrome X: 6 years later. *J Intern Med Suppl*, 1994 736, s. 13–22.
- Miranda, P. J. – DeFronzo, R. A. – Califf, R. M., et al.: Metabolic syndrome: evaluation of pathological and therapeutic outcomes. *Am Heart J*, 2005, 149, s. 20–32.
- DeFronzo, R. A.: Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. *Diabetes*, 1988, 37, s. 667–687.
- DeFronzo, R. A. – Bonadonna, R. C. – Ferrannini, E.: Pathogenesis of NIDDM. A balanced overview. *Diabetes Care*, 1992, 15, s. 318–368.
- DeFronzo, R. A. – Ferrannini, E.: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. *Diabetes Care*, 1991, 14, s. 173–194.
- Grundy, S. M.: Pre-diabetes, metabolic syndrome, and cardiovascular risk. *J Am Coll Cardiol*, 2012, 59, s. 635–643.
- Mottilo, S. – Filion, K. B. – Genest, J., et al.: The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. *J Am Coll Cardiol*, 2010, 56, s. 1113–1132.
- Haffner, S. M. – Stern, M. P. – Hazuda, H. P., et al.: Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? *JAMA*, 1990, 263, s. 2893–2898.
- International Diabetes Federation Guideline Development Group. Guideline for management of postmeal glucose in diabetes. *Diabetes Res Clin Pract*, 2014, 103, s. 256–268.
- Ceriello, A. – Colagiuri, S.: International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations. *Diabet Med*, 2008, 25, s. 1151–1156.
- Raz, I. – Riddle, M. C. – Rosenstock, J., et al.: Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. *Diabetes Care*, 2013, 36, s. 1779–1788.
- Dostupné z: <http://www.diab.cz/standardy>.
- Brož, J. – Honěk, P. – Dušek, L., et al.: The mortality of patients with diabetes mellitus using oral antidiabetic drugs in the Czech Republic decreased over the decade of 2003–2013 and came closer to the population average. *Vnitř Lek*, 2015, 61, suppl. 3, s. 3514–3520.
- Kvapil, M.: The SPACE project (Stav Pacientů Akceptovaných diabetologem Cestou Exportu/The Health Records of Patients Accepted by a Diabetologist by way of Export). *Vnitř Lek*, 2016, 62, suppl. 3, s. 22–27.
- Khunti, K. – Gomes, M. B. – Pocock, S., et al.: Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. *Diabetes Obes Metab*, 2017, doi: 10.1111/dom.13088.
- Reach, G. – Pechter, V. – Gentilella, R., et al.: Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. *Diabetes Metab*, 25. 7. 2017, doi: 10.1016/j.diabet.2017.06.003, Epub před tiskem.
- Inzucchi, S. E.: Is it time to change the type 2 diabetes treatment paradigm? No! Metformin should remain the foundation therapy for type 2 diabetes. *Diabetes Care*, 2017, 40, s. 1128–1132.
- Abdul-Ghani, M. – DeFronzo, R. A.: Is it time to change the type 2 diabetes treatment paradigm? Yes! GLP-1 RAs should replace metformin in the type 2 diabetes algorithm. *Diabetes Care*, 2017, 40, s. 1121–1127.

Průduškové astma a chronická obstrukční plicní nemoc

prof. MUDr. Jiří Homolka, DrSc. I. klinika tuberkulózy a respiračních nemocí VFN a 1. LF UK, Praha

- Agusti, A., et al.: GOLD Report 2017, 136 s.
- Calverley, P. M. A., et al.: A randomised, placebo-controlled trial of anit-interleukin 1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary diseases. *Respir Res*, 2017, 18, s. 153–160.
- Calverley, P. M. A., et al.: Reported pneumonia in patients with COPD: findings from the INSPIRE study. *Chest*, 2011, 139, s. 505–512.
- Kašák, V.: Diferenciální diagnóza asthma bronchiale a chronické obstrukční plicní nemoci. *Alergie*, 2000, 2, s. 107–119.
- Kitaguchi, Y., et al.: Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. *Int J Chron Obstruct Pulmon Dis*, 2012, 7, s. 283–289.
- Kolek, V., et al.: *Doporučené postupy v pneumologii*. Maxdorf, Praha 2016, s. 16–126.
- Lakshmi, S. P. – Reddy, A. T. – Reddy, R. C.: Emerging pharmaceutical therapies for COPD. *Int J COPD*, 2017, 12, s. 2141–2156.
- Miravittles, M., et al.: A review of national guidelines for management of COPD in Europe. *Eur Respir J*, 2016, 47, s. 625–637.
- Reddel, H. K., et al.: A summary of the new GINA strategy: a roadmap to asthma control. *Eur Respir J*, 2015, 46, s. 622–639.
- Vondra, V.: *Chronická obstrukční plicní nemoc*. Vltavín, Praha, 1998, s. 5–46.

Radioterapie v léčbě maligních nádorů kůže nemelanomového typu

MUDr. Hana Doleželová Ph.D. | MUDr. Petra Hübnerová Klinika radiační onkologie, MOÚ, Brno

- Kubecová, M.: *Maligní nádory kůže nemelanomového typu z pohledu radiačního onkologa*. Referátový výběr z onkologie. 2012
- Šlampa, P., a kol.: *Radiační onkologie v praxi*. Brno 2014.
- Šlampa, P. – Petera, J.: *Radiační onkologie*. Galén, Praha, 2008.

Sekundární osteoporóza u zánětlivých revmatických onemocnění

MUDr. David Suchý, Ph.D. Oddělení klinické farmakologie FN Plzeň, Ústav farmakologie 2. LF UK, Praha

MUDr. Radka Fuchsová Centrální radioizotopová laboratoř LF UK a FN Plzeň

- NIH consensus development panel on osteoporosis prevention, diagnosis, and therapy. *JAMA*, 2001, 285, s. 785–795.
- Sinaglia, L. – Varenna, M. – Girasole, G., et al.: Epidemiology of osteoporosis in Rheumatic diseases. *Rheum Dis Clin N Am*, 2006, 32, s. 631–658.
- Geusens, P.: The role of RANK ligand/osteoprotegerin in rheumatoid arthritis. *Ther Adv Musculoskel Dis*, 2012, 4, s. 225–233.
- van Staa, T. P. – Leufkens, H. G. – Cooper, C.: The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. *Osteoporos Int*, 2002, 13, s. 777–787.
- Sinaglia, L. – Nervetti, A. – Mela, Q., et al.: A multicentre cross sectional study on bone mineral density in rheumatoid arthritis. *J Rheumatol*, 2000, 27, s. 2582–2589.
- Haugenberg, G. – Uhlig, T. – Falch, J. A., et al.: Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis. *Arthritis Rheum*, 2000, 43, s. 522–530.
- Stafford, L. – Bleasel, J. – Giles, A., et al.: Androgen deficiency and bone mineral density in men with rheumatoid arthritis. *J Rheumatol*, 2000, 27, s. 2786–2790.
- Van Staa, T. P. – Geusens, P. – Bijlsma, W. J., et al.: Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. *Arthritis Rheum*, 2006, 54, s. 3104–3112.
- Ørstavik, R. E. – Haugeberg, G. – Mowinckel, P., et al.: Vertebral deformities in rheumatoid arthritis. *Arch Intern Med*, 2004, 164, s. 420–425.
- de Nijs, R. N. J. – Jacobs, J. W. G. – Bijlsma, J. W. J., et al.: On behalf of the Osteoporosis Working Group of the Dutch Society for Rheumatology. Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis. *Rheumatology*, 2001, 40, s. 1375–1383.
- Spector, T. D. – Hall, G. M. – Mc Closkey, E. V., et al.: Risk of vertebral fracture in women with rheumatoid arthritis. *BMJ*, 1993, 306, s. 558.
- Ørstavik, R. E. – Haugeberg, G. – Uhlig, T., et al.: Self reported non-vertebral fractures in rheumatoid arthritis and population based

- controls: incidence and relationship with bone mineral density and clinical variables. *Ann Rheum Dis*, 2004, 63.
- 13 Lee, Ch. – Ramsey-Goldman, R.: Osteoporosis in systemic lupus erythematosus mechanism. *Rheum Dis Clin N Am*, 2005, 31, s. 363–385.
 - 14 Uratawong, S. – Deesomchoke, U. – Lertmaharit, S.: Bone mineral density in premenopausal women with systemic lupus erythematosus. *J Rheumatol*, 2003, 30, s. 2365–2368.
 - 15 Sinigaglia, L. – Varena, M. – Binelli, L., et al.: Determinants of bone mass in systemic lupus erythematosus: a cross sectional study on premenopausal women. *J Rheumatol*, 1999, 26, s. 1280–1284.
 - 16 Pons, F. – Peris, P. – Guanabens, N., et al.: The effect of systemic lupus erythematosus long term steroid therapy on bone mass in premenopausal women. *Br J Rheumatol*, 1995, 34, s. 742–746.
 - 17 Bhattoa, H. P. – Kiss, E. – Bettembuk, P., et al.: Bone mineral density, biochemical markers of bone turnover, and hormonal status in men with systemic lupus erythematosus. *Rheumatol Int*, 2001, 21, s. 97–102.
 - 18 Housieau, F. A. – Lefebvre, C. – Depresseux, G., et al.: Trabecular and cortical bone loss in systemic lupus erythematosus. *Br J Rheumatol*, 1996, 35, s. 242–247.
 - 19 Pettila, V. – Leinonen, P. – Markkola, A., et al.: Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. *Tromb Hemost*, 2002, 11, s. 680–682.
 - 20 Ramsey Goldmann, R. – Dunn, J. E. – Huang, C. F., et al.: Frequency of fractures in women with systemic lupus erythematosus: Comparison with United States population data. *Arthritis Rheum*, 1999, 42, s. 882–890.
 - 21 Gordon, C.: Long term complications of systemic lupus erythematosus. *Rheumatology*, 2002, 41, s. 1095–1100.
 - 22 Loucks, J. – Pope, J. E.: Osteoporosis in scleroderma. *Seminars in Arthritis and Rheumatism*, 2005, 34, s. 678–682.
 - 23 Souza, R. B., et al.: Systemic sclerosis and bone loss: The role of the disease and body composition. *Scand J Rheum*, 2006, 35, s. 384–387.
 - 24 Ibn Yacoub, Y., et al.: Bone density in Moroccan women with systemic sclerosis and its relationships with disease-related parameters and vitamin D status. *Rheum Int*, 2012, 32, s. 3143–3148.
 - 25 Yuen, S. Y., et al.: Patients with scleroderma may have increased risk of osteoporosis. A comparison to rheumatoid arthritis and noninflammatory musculoskeletal conditions. *J Rheum*, 2008, 35, s. 1073–1078.
 - 26 Alsufyani, K. A., et al.: Bone mineral density in children and adolescents with systemic lupus erythematosus, juvenile dermatomyositis, and systemic vasculitis: relationship to disease duration, cumulative corticosteroid dose, calcium intake, and exercise. *J Rheum*, 2005, 32, s. 729–733.
 - 27 Castro, T. C., et al.: Bone mineral density of Brazilian girls with juvenile dermatomyositis. *Brazilian J Med Biol Res*, 2005, 38, s. 309–313.
 - 28 Mathiesen, P. R., et al.: Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients. *Clin Exp Rheum*, 2010, 28, s. 782–789.
 - 29 Ng, K. P., et al.: Concomitant diseases in a cohort of patients with idiopathic myositis during long-term follow-up. *Clin Rheum*, 2009, 28, s. 947–953.
 - 30 Antelava, O. A., et al.: Bone mineral density in idiopathic inflammatory myopathies. *Klinicheskaia Meditsina*, 2003, 81, s. 57–61.
 - 31 de Andrade, D. C., et al.: High frequency of osteoporosis and fractures in women with dermatomyositis/polymyositis. *Rheumatology International*, 2012, 32, s. 1549–1553.
 - 32 Pavelka, K.: *Revmatologie*. Praha, Maxdorf, 2012, s. 295–297.
 - 33 Klinberg, E. – Lorentzon, M. – Melström, D., et al.: Osteoporosis in ankylosing spondylitis-prevalence, risk factors and methods of assessment. *Arthritis Research & Therapy*, 2012, 14, R108.
 - 34 Sambrook, P. N. – Geusens, P.: The epidemiology of osteoporosis and fractures in ankylosing spondylitis. *Ther Adv Musculoskelet Dis*, 2012, 4, s. 287–292.
 - 35 Murray, G. C. – Persellin, R. H.: Cervical fracture complicating in ankylosing spondylitis: a report of eight cases and review of the literature. *Am J Med*, 1981, 70, s. 1033–1041.
 - 36 Grisolia, A. – Bell, R. – Peltier, L.: Fractures and dislocations of the spine complicating ankylosing spondylitis. *J Bone Joint Surg Am*, 1967, 49, s. 339–344.
 - 37 Lange, U. – Teichmann, J. – Muller-Ladner, U., et al.: Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF- α antibody: a prospective open-label pilot study. *Rheumatology*, 2005, 44, s. 1546–1548.
 - 38 Reid, D. M. – Devogelaer, J. P. – Saag, K., et al.: Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. *Lancet*, 2009, 373, s. 1253–1263.

Moderní léčba kašle

MUDr. Stanislav Kos, CSc., FCCP Český občanský spolek proti plicním nemocem, Praha

- 1 Čáp, P. – Vondra V., et al.: *Akutní a chronický kašel*. Mladá fronta Praha, 2013.
- 2 Juřica, J.: Farmakoterapie kašle ve zkratce. *Medicina pro praxi*, 2016, 13, s. 268–274.
- 3 Catena, E.: Efficacy and tolerability of levodropropizine in adult patients with non productive cough. Comparison with dextromethorphan. *Pulm Pharmacol Ther*, 1997, 10, s. 89–96.
- 4 Luporini, G., et al.: Efficacy and safety levodropropizine and dihydrocodeine on non productive cough in primary and metastatic lung-cancer. *Eur Respir J*, 1998, 12, s. 97–101.
- 5 Dal Negro, R. W., et al.: Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. *Eur Respir J*, 2017, 50, 1700711.
- 6 Kopřiva, F.: Sledování ATB léčby dětských pacientů s recidivujícími respiračními infekcemi v letech 2013–2015 a erdosteinu, aneb co nám řekla „ERICA“. *Vox Paediatricae*, 2017, 1.

Betablokátory a srdeční selhání

prof. MUDr. Jindřich Špinar, CSc., FESC Interní kardiologická klinika, LF MU a FN Brno

prof. MUDr. Jiří Vítovec, CSc., FESC | prof. MUDr. Lenka Špinarová, Ph.D., FESC

Interní kardiologická klinika, LF MU a FNUSA, Brno

- 1 The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC): 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*, 2016, doi:10.1093/eurheartj/ehw128.
- 2 Špinar, J. – Vítovec, J. – Hradec, J., et al.: Czech Society of Cardiology guidelines for the diagnosis and treatment of chronic heart failure. *Cor et Vasa*, 2012, 54, s. 113–134.
- 3 Špinar, J. – Vítovec, J. – Hradec, J., et al.: Doporučený postup České kardiologické společnosti pro diagnostiku a léčbu chronického srdečního selhání 2011. *Cor et Vasa*, 2012, 54, s. 161–184.
- 4 Mosterd, A. – Hoes, A. W.: Clinical epidemiology of heart failure. *Heart*, 2007, 93, s. 1137–1146.
- 5 Vítovec, J. – Špinarová, L. – Špinar, J.: Sacubitril-valsartan (LCZ696) v léčbě srdečního selhání. *KARIM*, 2016, 18, s. 125–129.
- 6 Špinar, J. – Vítovec, J. – Špinarová, L.: Hot lines z ACC 2016, Chicago. *KARIM*, 2016, 18, s. 133–136.
- 7 Bangalore, S. – Messeri, F. H. – Kostis, J. B., et al.: Cardiovascular protection using beta-blockers: a critical review of the evidence. *J Am Coll Cardiol*, 2007, 50, s. 563–572.
- 8 Bangalore, S. – Bhatt, D. L. – Steg, P. G., et al.: β -blockers and cardiovascular events in patients with and without myocardial infarction. Post hoc analysis from the CHARISMA trial. *Circ Cardiovasc Qual Outcomes*, 2014, 7, s. 872–881.
- 9 Bangalore, S. – Makani, H. – Radford, M., et al.: Clinical outcomes with β -blockers for myocardial infarction: a meta-analysis of randomized trials. *Am J Med*, 2014, 127, s. 939–953.
- 10 Dubrava, J.: Prieskum „3P pri srdcovom zlyhavani“ so zameraním na srdcovú frekvenciu. *Vnitř Léč*, 2016, 62, s. 17–24.
- 11 Vítovec, J. – Špinar, J.: Beta-blockers in the treatment of chronic heart failure. How should results of clinical studies be introduced into clinical practice. *Vnitř Léč*, 2000, 46, s. 161–165.
- 12 Waagstein, F. – Hjalmarson, A. – Varnauskas, E., et al.: Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. *British Heart Journal*, 1975, 37, s. 1022–1036.
- 13 Waagstein, F. – Bristow, M. R. – Swedberg, K., et al.: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy: Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Groups. *Lancet*, 1993, 344, s. 1441–1446.
- 14 Widimský, J.: Betablokátory skutečně snižují mortalitu nemocných se srdečním selháním (včetně aktuálních výsledků studie Merit-HF Study Group). *Cor Vasa*, 1999, 41, s. 317–319.
- 15 Widimský, J.: Betablokátory v léčbě srdečního selhání. *JAMA-CS*, 1999, 7, s. 375–377.
- 16 Swedberg, K. – Hjalmarson, A. – Waagstein, F., et al.: Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. *Lancet*, 1979, 1, s. 1374–1376.
- 17 The MERIT-HF Study Group: Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients With Heart Failure. Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). *JAMA*, 2000, 283, s. 1295–1302.
- 18 Lábr, K. – Špinar, J. – Pařenica, J. – Špinarová, L. – Málek, F. – Špinarová, M. – Ludka, O. – Jarkovský, J. – Benešová, K. – Lábrová, R.: Betablokátory v registru chronického srdečního selhání FAR NHL. *Kardiologická revue a Int Med*, 2017, 19, s. 68–72.

Použití fixní trojkombinace atorvastatin, perindopril a amlodipin k terapii arteriální hypertenze a ke snížení rizika kardiovaskulárních příhod

doc. MUDr. Filip Málek, Ph.D. Kardiovaskulární centrum Nemocnice na Homolce, Praha

- 1 Filipovský, J. – Widimský, J. Jr. – Ceral, J., et al.: Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi. *Hypertenze a kardiovaskulární prevence*, 2012, 3, s. 1–16.
- 2 Soška, V. – Vaverková, H. – Vrablík, M., et al.: Stanovisko výboru ČSAT k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2011. *Vnitřní Léč*, 2013, 59, s. 120–126.
- 3 Thom, S. – Poulter, N. R. – Field, J., et al.: Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. *JAMA*, 2013, 310, s. 918–929.
- 4 Bertrand, M. E. – Vlachopoulos, Ch. – Mourad, J. J.: Triple combination therapy for global cardiovascular risk: atorvastatin, perindopril, and amlodipin. *Am J Cardiovasc Drugs*, 2016, 16, s. 241–253.

Arteriální hypertenze a antikoagulační léčba u starších a starých pacientů

MUDr. Antonín Novák EUC Klinika, kardiologická ambulance, Ústí nad Labem

- 1 Blood Pressure Lowering Treatment Trialists Collaboration: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. *Lancet*, 2003, 362, s. 1527–1535.
- 2 Collins, R. – Peto, R. – MacMahon, S., et al.: Blood pressure, stroke, and coronary heart disease, II: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. *Lancet*, 1990, 335, s. 827–838.
- 3 Gage, B. F. – van Walraven, C. – Pearce, L., et al.: Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. *Circulation*, 2004, 110, s. 2287–2292.
- 4 Fuster, V. – Ryden, L. E. – Asinger, R. W., et al.: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation (A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology). *Eur Heart J*, 2001, 22, s. 1852–1923.
- 5 de Haïat, R. – Leroy, G.: *Empfehlungen und Vorgaben in der Kardiologie*. Frison-Roche. Allemand, 2015, s. 18.
- 6 SHEAF Self measurement of blood pressure at home in the elderly: assessment and follow-up. *Arch Intern Med*, 2001, 161, s. 2205–2211.
- 7 Staessen, J. A. – Fagard, R. – Thijs, L., et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. *Lancet*, 1997, 350, s. 757–764.
- 8 Gayet, J.-L.: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. *J Hyper*, 2003, 21, s. 1771.
- 9 PROGRESS: Perindopril pRotection aGainst REcurrent Stroke Study. *Lancet*, 2001, 358, s. 1225–1237.
- 10 Gueyffier, F. – Bulpitt, Ch. – Boissel, J.-P., et al.: Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. *INDANA Lancet*, 1999, 353, s. 793–793.
- 11 de Haïat, R. – Leroy, G.: *Empfehlungen und Vorgaben in der Kardiologie*. Frison-Roche. Allemand, 2015, s. 49.
- 12 Christopher, J. – Bulpitt, Ch.: Further results of the hypertension in the very elderly trial (HYVET). *Eng J Med*, 2008, 385, s. 1887–1897.
- 13 INVEST: INternational VErapamil SR Trandolapril STudy. *JAMA*, 2003, 290, s. 2805–2816.
- 14 Oparil, S.: Pathogenesis of hypertension. *Ann Intern Med*, 2003, 139, s. 761–776.
- 15 de Haïat, R. – Leroy, G.: *Empfehlungen und Vorgaben in der Kardiologie*. Frison-Roche. Allemand, 2015, s. 239.
- 15 ESC Clinical Practice Guidelines 2016.
- 16 Zápis z jednání mezi zástupci VZP ČR, České kardiologické společnosti a Sdružení ambulantních specialistů ze dne 22. 4. 2015.
- 17 Levey, A. S. – Bosch, J. P. – Lewis, J. B., et al.: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. *Am Intern Med*, 1999, 130, s. 461–470.
- 18 Cockcroft, D. W. – Gault, M. H.: Prediction of creatinine clearance from serum creatinine. *Nephron*, 1976, 16, s. 31–41.

Preskripce statinů v ordinaci praktického lékaře

MUDr. Eva Tůmová, Ph.D. Centrum preventivní kardiologie, III. interní klinika 1. LF UK a VFN, Praha

- 1 Stone, N. J. – Robinson, J. – Liechtenstein, A. H., et al.: 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circ*, 2014, 129, s. 59.
- 2 Canon, C. P. – Blazing, M. A. – Giugliano, R. P., et al.: Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med*, 2015, 372, s. 2387–2397.
- 3 Filipovský, J. – Widimský, J. Jr. – Ceral, J., et al.: Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi. *Vnitřní Léč*, 2012, 58, s. 785–801.
- 4 Soška, V. – Vaverková, H. – Vrablík, M., et al.: Stanovisko výboru ČSAT k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2011. *DMEV*, 2013, 16, s. 24–29.
- 5 Catapano, A. L. – Graham, I. – De Backer, G., et al.: 2016 ESC/EAS Guidelines for the management of dyslipidaemias. *EHL*, 2016, 253, s. 281–344.
- 6 Pyörälä, K. – De Backer, G. – Graham, I., et al.: Prevention of coronary heart disease in clinical practice: recommendations of the task force of the European Society of Cardiology, European Atherosclerosis Society and European society of Hypertension. *Atherosclerosis*, 1994, 110, s. 121–161.
- 7 Leeper, N. J. – Ardehali, R. – deGoma, E. M., et al.: Statin use in patients with extremely low low-density lipoprotein levels is associated with improved survival. *Circulation*, 2007, 116, s. 613–618.
- 8 Nissen, S. E. – Nicholls, S. J. – Sipahi, I., et al.: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. *JAMA*, 2006, 295, s. 1556–1565.
- 9 Boekholdt, S. M. – Hovingh, G. K. – Mora, S., et al.: Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. *J Am Coll Cardiol*, 2014, 64, s. 485–494.
- 10 Cholesterol Treatment Trialists' (CTT) Collaborators: Mihaylova, B. – Emberson, J., et al.: The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet*, 2012, 380, s. 581–590.
- 11 Hradec, J. – Bultas, J. – Kmínek, A., et al.: Jak se léčí statiny v České republice? *CorVasa*, 2011, 53, s. 527–534.
- 12 Newman, C., et al.: Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. *Am J Cardiol*, 2006, 97, s. 61–67.
- 13 LaRosa, J. C. – Grundy, S. M. – Waters, D. D., et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med*, 2005, 352, s. 1425–1435.
- 14 Sabatine, M. S. – Giugliano, R. P. – Keech, A. C., et al.: Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*, 2017, 376, s. 1713–1722.